These newer therapies, including Semaglutide , belong to a group of drugs called GLP-1 receptor agonists . Primarily developed for controlling type 2 diabetes , they work by assisting the body to release sufficient insulin and limiting increased glucose levels. Beyond diabetes, their ability to p